Saturday 17 October 2026
Export ENSC’s income statement to Excel — free account
Ensysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 15.1%, EPS grew 74.7% and free cash flow grew 27.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.52
0.08
−13.33%
Follow ENSC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.84 | 0.78 | 0.46 | 1.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.93) | (1.05) | (1.54) | (3.67) | |
P/B ratio |
0.00 | 0.00 | 0.82 | 7.82 | |
Price to Tangible BV |
0.00 | 0.00 | 0.82 | 7.82 | |
EV/Sales |
0.87 | 0.80 | (0.23) | 1.33 | |
EV/EBITDA |
0.00 | 0.00 | 0.11 | 0.00 | |
EV/Operating CF |
(0.44) | (0.39) | 0.15 | (0.85) | |
EV/FCF |
(0.44) | (0.39) | 0.15 | (0.85) | |
Quick Ratio |
0.27 | 0.26 | 1.04 | 0.73 | |
Current Ratio |
0.70 | 0.71 | 1.59 | 1.27 | |
Net Debt/EBITDA |
0.26 | 0.21 | 1.55 | 0.45 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.06 | 1.39 | 0.78 | 0.71 | |
Operating CF/Net income |
0.76 | 0.98 | 0.55 | 0.50 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Interest Coverage |
(8,588.00) | (913.38) | (515.15) | (584.55) | |
Research and Development Expense of Revenue |
212.30% | 348.27% | 191.95% | 599.25% | |
Selling, General and Administrative Expense of Revenue |
108.99% | 122.40% | 55.84% | 259.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.16% | 0.91% | 1.30% | (10.20%) | |
Graham Net Nets |
(0.32) | (0.22) | 1.14 | 0.09 | |
Graham Number |
2.30 | 2.72 | 0.00 | 0.00 | |
Earnings Yield |
(951.72%) | (620.37%) | (458.70%) | (268.78%) | |
Free Cash Flow Yield |
(234.24%) | (259.94%) | (331.84%) | (102.99%) | |
Revenue per Share |
0.09 | 0.14 | 0.74 | 0.17 | |
Operating CF per Share |
(0.15) | (0.51) | (0.60) | (0.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.15) | (0.51) | (0.60) | (0.65) | |
Cash per Share |
0.05 | 0.11 | 1.69 | 0.58 | |
Shareholders Equity per Share |
(0.09) | (0.10) | 1.13 | 0.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.09) | (0.10) | 1.13 | 0.30 | |
Free Cash Flow |
(1.96) | (3.50) | (1.53) | (1.87) | |
Working Capital |
(1.22) | (0.83) | 2.68 | 0.62 | |
Capital Expenditures |
— | — | (0.12) | — | |
Net Current Asset Value |
(1.22) | (0.83) | 2.68 | 0.62 | |
EV/EBIT |
0.00 | 0.00 | 0.11 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.22 | — | 0.27 | 0.89 | |
Average Payables |
1.51 | 1.11 | 2.31 | 1.22 | |
Average Assets |
4.27 | 3.39 | 6.52 | 6.28 | |
Average Common Equity |
0.97 | 1.03 | 3.13 | 3.73 |
Columns are period end dates